Future directions in the treatment of ovarian cancer

This publication has 17 references indexed in Scilit:

• Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma
  Seminars in Oncology, 2002
• Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)
  Seminars in Oncology, 2002
• Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
  Journal of Clinical Oncology, 2001
• Effective Dosing of Topotecan With Carboplatin in Relapsed Ovarian Cancer: A Phase I/II Study
  Journal of Clinical Oncology, 2001
• Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2001
• Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer
  Journal of Clinical Oncology, 2001
• Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
  Journal of Clinical Oncology, 2001
• Cancer Statistics, 2001
  CA: A Cancer Journal for Clinicians, 2001
• Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
  Journal of Clinical Oncology, 2000
• Cellular Response to a GlutathioneS-Transferase P1-1 Activated Prodrug
  Molecular Pharmacology, 2000